Destination XL (DXLG) Tender Offer Expires: 23% Tendered, Zero Shares Bought

TL;DR

• Zodiac Partners II let its $0.84-a-share, roughly $46.4 million all-cash tender offer for Destination XL Group (DXLG) expire on August 21 without buying a single share, even though 12,450,814 shares, about 23% of the float, were validly tendered.
• DXLG closed Monday, August 24 at $0.6361, up 4.38%, still about 24% below the offer Zodiac just walked away from.
• Zodiac's stated reason: DXL's board is contractually bound to a rival deal, the FullBeauty Brands "merger of equals," which DXL's own board now tells shareholders to vote against.
• That board reversal, announced July 21, cited FullBeauty's debt load, a possible negative equity value, and dilution that would leave DXL holders with just 45% of the combined, $1.2 billion-revenue company.
• Walking away from FullBeauty isn't free either: DXL owes a termination fee near $3.45 million if FullBeauty pulls out over the board's reversal. The two sides just extended the agreement's own outside deadline to October 30, 2026, with still no shareholder vote scheduled.

The Board

Zodiac's $0.84 tender offer expired Aug 21, 2026 without a single purchase.

Why Did Destination XL's Tender Offer Expire Without a Sale?

Zodiac let its own offer lapse on purpose. The firm's own release, syndicated via GlobeNewswire says its all-cash tender for Destination XL Group (DXLG), raised to $0.84 a share back in June, expired at 5:00pm ET on August 21 with 12,450,814 shares validly tendered, and closed the book at zero shares purchased.

That share count works out to a little over 22.5% of the 55,273,092 shares DXL reported outstanding as of mid-June, which Zodiac rounds to "nearly a quarter." Both numbers describe the same thing: a real chunk of the shareholder base said yes to $0.84 a share, and Zodiac still walked away.

Ziggy Gokea, Zodiac's managing member, put the reasoning on the record: "Nearly a quarter of DXL shares came to us, but due to the onerous terms of the FBB Merger Agreement, we feel DXL cannot do what is in the best interest of shareholders." Translated, Zodiac's tender couldn't close cleanly while DXL remains bound to a separate, signed merger agreement with FullBeauty Brands, and rather than fight that agreement through a tender structure, Zodiac chose to let its own offer die and push for a negotiated deal instead.

A Board That Turned On Its Own Merger

DXL and FullBeauty Brands announced their "merger of equals" on December 11, 2025, pitching a combined apparel retailer with about $1.2 billion in trailing revenue through October 2025 and roughly $45 million of standalone adjusted EBITDA, rising toward $70 million with $25 million of expected cost synergies. DXL's board approved it unanimously at signing.

By July 21, 2026, that same board had reversed course, filing proxy materials that urge shareholders to vote against the deal. The stated reasons, in the company's own words from its SEC filing: "the increasingly challenging consumer environment since the execution of the merger agreement," FullBeauty's "level of indebtedness and related concerns regarding FullBeauty's potential negative equity value," and "the substantial economic dilution that DXL stockholders would experience if the merger were consummated on its current terms."

That dilution number is the one to focus on. Under the original terms, FullBeauty's holders would own 55% of the combined company and DXL's own shareholders just 45%, all in exchange for taking on a business the board itself now questions the solvency of. A board that signs a deal in December and asks shareholders to kill it in July isn't hedging. It's saying the original math stopped working.

What FullBeauty Still Costs to Walk Away From

The FullBeauty agreement isn't dead, and that's the part making this messy. FullBeauty holders and debt holders committed to a $92 million equity subscription at closing, mixing new equity with debt equitized into a $172 million term loan maturing August 2029. None of that has been triggered because no shareholder vote has been scheduled at all, for a deal DXL originally expected to close in the first half of its fiscal 2026, a window that closed at the end of July with nothing resolved.

The two sides kept the clock running anyway. On August 19, two days before Zodiac's tender expired, DXL and FullBeauty amended the merger agreement to push its outside termination date from September 11 to October 30, 2026, with, per the filing, no other terms changed. That is the real deadline to watch now: either a shareholder vote happens before October 30, or the agreement's own clock runs out.

If FullBeauty exercises its right to terminate over DXL's changed recommendation, DXL owes a $2.5 million termination fee plus up to $950,000 in expense reimbursement, close to $3.45 million combined. Against a company worth roughly $35 million at Monday's close, that's not pocket change, and it's the reason DXL can't simply ignore FullBeauty and take Zodiac's cash: the agreement is still binding until someone formally ends it.

Zodiac's Next Move

Zodiac says it's "confident that, if granted appropriate access, it can negotiate and execute a definitive agreement within 45 days, and it is prepared to engage immediately." That's a bet DXL's board will eventually choose a clean cash exit over a stock swap into a company it has publicly called financially shaky. It's also Zodiac's second attempt at pressuring the board this way: the firm opened at $0.82 a share in May, raised to $0.84 in June alongside extra committed equity financing, extended the deadline more than once, and only let the clock finally run out this week.

Nothing in Zodiac's statement commits it to a third tender at a higher price. The 45-day ask reads as an attempt to get a seat at the negotiating table DXL's board hasn't offered it. It commits Zodiac to nothing about bringing the cash offer back.

A 64-Cent Stock Doesn't Get an Easy Trade

DXLG trades under a dollar, and that closes off most of the ordinary ways to express a view on it. Options exist in name on major data platforms, with expirations listed out to March 2027, but every chain checked for this piece came back with no populated strikes, no quoted premiums, and no visible open interest. A microcap that thin doesn't support a priced options structure, and pretending otherwise with a synthetic implied-volatility number would be inventing a figure this site doesn't have.

That leaves the common stock itself, and it's a binary bet on a governance fight, not a company. DXL could end up: taken out for cash if Zodiac and the board eventually strike a deal, diluted into the FullBeauty combination if a shareholder vote ever happens and passes, or stuck exactly where it is, running as a standalone retailer that hasn't been able to close either alternative in nine months of trying.

The Options Angle

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Conviction	Breakeven
1	Pass	Any DXLG options structure	No populated chain sourced	N/A	$0.6361	Unverified	3/10	N/A
2	Pass	Long DXLG common, betting on a revived cash offer	N/A	N/A	$0.6361	N/A	4/10	needs a fresh tender above $0.84 to beat Zodiac's lapsed price

I'm not comfortable calling a direction here. A stock that a board itself says could be worth negative equity in one merger scenario, and worth at least $0.84 in cash in another that just fell through, isn't mispriced so much as unresolved. That's a reason to watch DXL's next SEC filing. It isn't a reason to buy or sell the stock.

The One-Line Read

Destination XL's board rejected the merger it signed, and the buyer who could have rescued shareholders from it let his own cash offer expire instead of forcing the issue: two exits, and neither one closed.

Related coverage: Arbutus's Dutch auction tender offer math, how the RE/MAX cash-or-stock election played out under a similar proration squeeze, and the full scored history of calls like these two passes in the Track Record ledger.